This study aimed to assess the effects of different arginine (Arg) to lysine (Lys) ratios on feed intake, nutrient digestibility, growth performance, carcass characteristics, and antibody titers of Newcastle disease (ND) and infectious bronchitis (IB) disease in broilers during 35 days of trial. For this purpose, a total of 816 day-old broiler birds having an average weight of 38 ± 3 g were divided into six dietary treatments in such a way that each treatment had eight replicates and each replicate had 17 birds. The treatments were 0.95 (1.19/1.25, 1.12/1.18, and 1.05/1.1), 1 (1.25/1.25, 1.18/1.18, and 1.1/1.1), 1.05 (1.31/1.25, 1.24/1.18, and 1.17/1.1), 1.10 (1.38/1.25, 1.30/1.18, and 1.23/1.1), 1.15 (1.44/1.25, 1.36/1.18, and 1.28/1.1), and 1.20 (1.50/1.25, 1.42/1.18, and 1.34/1.1) Arg/Lys divided into different amounts according to the nutritional needs of starter, grower, and finisher diets, respectively. The results showed that in the finisher phase, the FI was influenced cubically, while in the overall period, a quadratic effect was observed for the FI ( < 0.05). The results of BWG showed that BWG was linearly increased in birds given different Arg/Lys in the grower, finisher, and overall period ( < 0.05). The results also showed that during the grower, finisher, and overall phases, the body weight gain (BWG) was better in birds fed with 1.05 and 1.10 Arg/Lys ( < 0.05). Furthermore, a better feed conversion ratio (FCR) was shown in the starter and grower phases at 1.10 and 1.15 Arg/Lys ( < 0.05). The results of nutrient digestibility explored showed that the experimental treatments had a better effect ( < 0.05) on dry matter and crude fat digestibility in birds fed with 1.19/1.25, 1.12/1.18, and 1.05/1.1 and 1.25/1.25, 1.18/1.18, and 1.1/1.1 Arg/Lys in their diets while the crude protein digestibility remained unaffected with different treatments ( > 0.05). The treatments had no effect ( > 0.05) on relative organ weights, immune organs, and carcass characteristics. However, higher titers of ND and IBD were observed in birds fed with Arg/Lys of 1.38/1.25, 1.30/1.18, and 1.23/1.1 and 1.50/1.25, 1.42/1.18, and 1.34/1.1 in their diets ( < 0.05). Based on the results of the current study, it is concluded that the inclusion levels of 1.38/1.25, 1.30/1.18, and 1.23/1.1, and 1.44/1.25, 1.36/1.18, and 1.28/1.1 Arg/Lys resulted in better growth performance and immune response in the broiler birds, respectively. Therefore, adjusting the levels of Arg/Lys in feed is recommended to enhance broilers' growth performance and immune response.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3390/ani15020135 | DOI Listing |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759158 | PMC |
Pediatr Surg Int
January 2025
Division of Pediatric Surgery, Department of Surgery, University of Florida College of Medicine, PO Box 100119, Gainesville, FL, 32610-0119, USA.
Purpose: Initial recommendations for ECMO had relative contraindications for low birth weight (BW) or low gestational age (GA) babies. However, more recent literature has demonstrated improved and acceptable outcomes of ECMO in smaller neonates. The purpose of this study was to understand both utilization and survival in patients with lower GA and BW.
View Article and Find Full Text PDFInt Urol Nephrol
January 2025
Department of Nephrology, Jiangxi Medical College, The Second Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China.
Purpose: To clarify the causal association between cardiovascular proteins and diabetic nephropathy (DN) in Europeans.
Methods: The large genome-wide association study data of cardiovascular proteins and DN were used for this two-sample Mendelian randomization (MR) analysis. We took the Inverse variance weighted (IVW) as the primary method.
Cytotherapy
January 2025
Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Electronic address:
Background/aims: Human mesenchymal stromal cells (hMSC) are multipotent adult cells commonly used in regenerative medicine as advanced therapy medicinal products. The expansion of these cells in xeno-free supplements is highly encouraged by regulatory agencies due to safety concerns. However, the number of supplements with robust performance and consistency for hMSC expansion are limited.
View Article and Find Full Text PDFJ Infect Dev Ctries
December 2024
The Cancer Hospital Affiliated to Shandong First Medical University (Shandong Cancer Prevention Research Institute, Shandong Cancer Hospital), Jinan 250117, China.
Introduction: In this study, we analyzed the psychological aspects of coronavirus disease 2019 (COVID-19) patients who were discharged from the hospitals in Shanghai, China, and later had positive nucleic acid retest results for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant infection (re-positive COVID-19). The purpose was to gain clarity on the patients' needs and to provide evidence for the medical staff to deliver scientific and targeted health care to the patients.
Methodology: We screened patients who tested positive for SARS-CoV-2 Omicron variant infection by nucleic acid testing after having previously recovered from a COVID-19 infection and being discharged from Shanghai shelter hospitals or COVID-19-designated hospitals from April 3, 2022, to May 10, 2022.
Chin Med
January 2025
Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Background: Bear bile powder (BBP), a unique animal-derived medicine with anti-inflammatory and antioxidant effects, is used in Shexiang Tongxin dropping pills (STDP), which is applied to treat cardiovascular diseases, including acute myocardial infarction (AMI). The efficacy and compatibility mechanisms of action of BBP in STDP against cardiovascular diseases remain unclear. This study aimed to investigate the compatibility effects of BBP in STDP in rats with AMI.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!